Oncotarget. 2024 Apr 8;15:248-254. doi: 10.18632/oncotarget.28579.ABSTRACTAcute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably,...

Oncotarget. 2024 Mar 19;15:238-247. doi: 10.18632/oncotarget.28567.ABSTRACTA clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight...

Oncotarget. 2024 Mar 15;15:232-237. doi: 10.18632/oncotarget.28569.ABSTRACTHere, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual PFS in 15-20% of patients compared to first-generation TKIs. Since detecting a single resistant...

Oncotarget. 2024 Mar 14;15:175-198. doi: 10.18632/oncotarget.28564.ABSTRACTOur understanding of DNA G-quadruplexes (G4s) from in vitro studies has been complemented by genome-wide G4 landscapes from cultured cells. Conventionally, the formation of G4s is accepted to depend on G-repeats such that they form tetrads. However, genome-wide G4s characterized...

Oncotarget. 2024 Mar 14;15:200-218. doi: 10.18632/oncotarget.28565.ABSTRACTWe describe the analytical validation of NeXT Personal®, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal...

Oncotarget. 2024 Mar 14;15:199. doi: 10.18632/oncotarget.28519.NO ABSTRACTPMID:38484150 | DOI:10.18632/oncotarget.28519